FK506 is an immunosuppressive drug that inhibits T cell receptor-mediated signal transduction. This Invest. 1995. 96:727-732.)
Introduction
FK506, a macrolide lactone isolated from Streptomyces tsukbaenesis, is a potent immunosuppressive agent ( 1, 2) . It is used clinically in organ transplantation, such as liver, kidney, and pancreas (3, 4) . It is well accepted that FK506 acts by strongly inhibiting lymphokine production by T cells (5) (6) (7) . However, little is known about the in vivo immunosuppressive effects of FK506. Furthermore, in vivo FK506 studies have assessed its pharmacological effects on allograft survival but have not addressed its in vivo effect on T cell activation and immunosuppression. This study was prompted by several previous studies reporting the induction of immunological tolerance by FK506. We hypothesized that FK506 can establish immunological tolerance in vivo by affecting T cell apoptosis.
The establishment of T cell tolerance is known to occur primarily in the thymus gland, where autoreactive T cells are deleted by apoptosis (8, 9) . However, similar to thymocytes, peripheral T cells surviving thymic selection may undergo apoptosis by antigen-mediated stimulation (10, 11) . Apoptosis, also termed programmed cell death, is a signal-dependent suicide form of cell death and is required for the generation and maintenance of self-tolerance (12, 13) . Several stimuli induce apoptosis, including stimulation of T and B cells via antigen receptors, irradiation, and exposures to cytokines, such as TNF and TGF-f3 (14) (15) (16) (17) .
In the present series of experiments, we examined the in vivo effect of FK506 on the T cell activation-induced programmed cell death triggered by T cell receptor-mediated stimulation. Our results showed that in vivo FK506 treatment eliminated antigen-stimulated T cells through DNA fragmentation. Alloantigen-stimulated cytolytic T cells contribute to the rejection of transplanted allografts and graft-versus-host disease (GVHD).' The elimination of these activated cytolytic T cells may silence these phenomena. Our results suggest that FK506-induced apoptosis of antigen-stimulated T cells may represent one of the mechanisms of immunological tolerance.
Methods

Antibodies and reagents
Murine anti-CD3 specific monoclonal antibody (mAb) producing B cell hybridoma 2C11 (18) (Fig. 1) . We also analyzed the surface expression of CD4 and CD8 molecules on thymocytes after anti-CD3 Ab, CsA, or FK506 injection (Fig. 2) . In vivo anti-CD3 Ab administration reduced CD4+ CD8+ thymocytes. Treatment with anti-CD3 Ab and FK506 caused a more marked deletion of CD4+ CD8+ immature thymocytes compared with that observed with anti-CD3 Ab alone. But in vivo CsA treatment did not enhance the deletion of CD4+ CD8 + thymocytes induced by anti-CD3 Ab.
FK506 augmented SEB-induced thymic apoptosis in vivo. Administration of SEB, a bacterial superantigen, is known to induce the antigen-specific thymocyte elimination by apoptosis (22) . We investigated the effect of FK506 on SEB-induced thymic apoptosis. Analysis of DNA extracted from SEB (50 Isg) -injected mice thymocytes was performed using agarose gel electrophoresis. As shown in Fig. 3 A, some DNA fragmentation was observed in SEB-primed thymocytes 16 h after injection. However, DNA fragmentation was better enhanced in SEB-FK506-primed mice thymocytes. To determine whether the latter occurred selectively in SEB-activated thymocytes, we analyzed the DNA of SEB-reactive V/38-positive thymocytes. (Fig. 3 B) .
FK506 augmented peripheral T cell apoptosis induced by in vivo SEB administration. SEB (50 ig) was injected intravenously into mice that were killed 3 d later. As previously reported, after 2 h of in vitro culture, the DNA of SEB-primed spleen T cells had a ladder-like pattern, characteristic of apoptosis (10). On day 3 after SEB administration, FK506 (2 mg/kg), CsA (50 mg/kg), or PBS was injected into mice that were killed 6 h later. The spleen T cells were cultured for 2 h in vitro, and fragmented DNA was extracted and electrophoresed. Increased DNA fragmentation was detected in FK506-treated spleen T cells compared with PBS-treated spleen T cells. But the DNA fragmentation of CsA-treated spleen T cells was not changed compared with that of PBS-treated spleen T cells (Fig.  4 A) in vivo (Fig. 4 B) spleen T cells (Fig. 5 A) . However, the percentage of control Vf36+ CD4+ T cells in FK506-treated was not different from that of untreated mice (Fig. 5 B) . We measured the percentage A of CD4 + Vf8 + T cells using several PBS-or SEB-treated mice and confirmed that this enhancement on CD4+ Vf8+ T cell deletion was consistently induced by in vivo FK506 treatment (Table I ).
In vivo injection of SEB also induces a state of anergy in peripheral T cells, when T cells are challenged with SEB in vitro (23) . However, in vivo FK506 treatment failed to influence SEB-induced anergy state (data not shown).
Discussion
FK506 is a powerful immunosuppressant drug used clinically to prevent allograft rejection (1) (2) (3) (4) Our results demonstrated that CsA partially blocked anti-CD3-induced in vivo thymic apoptosis in agreement with a previous report (25) . Although both drugs have indistinguishable effect by blocking the transcription of IL-2 gene, CsA and FK506 may have a differential effect on thymic apoptosis in vivo. For example, CsA is responsible for the induction of T cell-mediated autoimmunity under certain circumstances (26, 27) . In contrast to the inhibitory effect on thymic apoptosis in vivo, repeated CsA injection increases the deletion of peripheral T cells stimulated by SEB (28) .
FK506 treatment improves immunosuppressive therapy for allograft rejection (29, 30) . Tolerance to allograft, induced by FK506, may be attributed to the molecular action of FK506 by inhibiting the signal transduction of alloactivated T cells. Our results suggest an additional possible mechanism for the immunological tolerance established by FK506. FK506 may induce tolerance to allograft by provoking the elimination of alloantigen-activated T cells by apoptosis. In this regard, Bishop et al. (31) recently demonstrated that FK506 prevented the generation of alloantigen-induced cytolytic and helper T lymphocytes by limiting the dilution assay. GVHD is also a systemic manifestation of transplanted T lymphocyte activation in response to alloantigen (32) . Furthermore, recent studies have demonstrated that FK506 treatment prolongs GVHD-free stage by removing alloantigen-stimulated donor T lymphocytes and that FK506 is superior to CsA in preventing GVHD stage (33, 34) .
These reports support our hypothesis that alloantigen-stimulated T cells may be deleted by in vivo FK506 treatment.
In summary, our results indicate that in vivo FK506 treatment eliminates antigen-stimulated T cells by apoptosis. This FK506-mediated elimination of activated T cells may represents a new mechanism of FK506-induced immunological tolerance to alloantigen.
